Related Experiment Video
Updated: Nov 27, 2025

Intracellular Refolding Assay
Published on: January 24, 2012
The stress-responsive kinase DYRK2 activates heat shock factor 1 promoting resistance to proteotoxic stress
Rita Moreno1, Sourav Banerjee1,2, Angus W Jackson1
1Division of Cellular Medicine, School of Medicine, University of Dundee, Dundee, Scotland, UK.
Abstract:
To survive proteotoxic stress, cancer cells activate the proteotoxic-stress response pathway, which is controlled by the transcription factor heat shock factor 1 (HSF1). This pathway supports cancer initiation, cancer progression and chemoresistance and thus is an attractive therapeutic target. As developing inhibitors against transcriptional regulators, such as HSF1 is challenging, the identification and targeting of upstream regulators of HSF1 present a tractable alternative strategy. Here we demonstrate that in triple-negative breast cancer (TNBC) cells, the dual specificity tyrosine-regulated kinase 2 (DYRK2) phosphorylates HSF1, promoting its nuclear stability and transcriptional activity. DYRK2 depletion reduces HSF1 activity and sensitises TNBC cells to proteotoxic stress. Importantly, in tumours from TNBC patients, DYRK2 levels positively correlate with active HSF1 and associates with poor prognosis, suggesting that DYRK2 could be promoting TNBC. These findings identify DYRK2 as a key modulator of the HSF1 transcriptional programme and a potential therapeutic target.
Insights
Dual specificity tyrosine-regulated kinase 2 (DYRK2) activates heat shock factor 1 (HSF1) in triple-negative breast cancer. Targeting DYRK2 may offer a new therapeutic strategy for TNBC by reducing HSF1 activity.
Area of Science:
- Molecular oncology
- Cellular stress response
Background:
- Cancer cells activate the proteotoxic-stress response pathway, regulated by heat shock factor 1 (HSF1), to survive.
- This pathway is crucial for cancer initiation, progression, and chemoresistance, making HSF1 an attractive therapeutic target.
- Targeting upstream regulators of HSF1 is a viable strategy due to challenges in inhibiting transcriptional regulators directly.
Purpose of the Study:
- To investigate the role of dual specificity tyrosine-regulated kinase 2 (DYRK2) as an upstream regulator of HSF1 in triple-negative breast cancer (TNBC).
- To determine if DYRK2 modulates HSF1 activity and influences TNBC cell survival under proteotoxic stress.
- To assess the clinical relevance of DYRK2 as a potential therapeutic target in TNBC.
Main Methods:
- Investigated the interaction between DYRK2 and HSF1 in TNBC cells.
- Assessed the effect of DYRK2 depletion on HSF1 phosphorylation, nuclear stability, and transcriptional activity.
- Evaluated the impact of DYRK2 on TNBC cell sensitivity to proteotoxic stress.
- Correlated DYRK2 and active HSF1 levels with patient prognosis in TNBC tumors.
Main Results:
- DYRK2 phosphorylates HSF1 in TNBC cells, enhancing its nuclear stability and transcriptional activity.
- Depletion of DYRK2 reduces HSF1 activity and sensitizes TNBC cells to proteotoxic stress.
- In TNBC patient tumors, DYRK2 levels positively correlate with active HSF1 and are associated with poor prognosis.
Conclusions:
- DYRK2 is a key upstream regulator of the HSF1 transcriptional program in TNBC.
- DYRK2 promotes TNBC progression and chemoresistance by modulating HSF1 activity.
- DYRK2 represents a potential therapeutic target for triple-negative breast cancer.
Related Concept Videos
Other Stress Responses in Bacteria
Regulation of the Unfolded Protein Response
The Unfolded Protein Response
Diversity of Archaea IV
Diversity of Archaea III
Bacterial Protein Maturation

